Company: SYRA
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001641172-25-023235
Chunk: 2

Company: Syra Health Corp
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 1
Chunk 2
---
    Research and development expenses 
     29,712  
     277,894  
     66,885  
     555,442 
  
    Selling, general and administrative expenses 
     289,070  
     456,572  
     576,357  
     858,837 
  
    Depreciation 
     5,978  
     17,374  
     12,775  
     29,919 
  
    Total operating expenses 
     816,053  
     1,740,360  
     1,878,543  
     3,363,601 

    Operating loss 
     (63,158) 
     (1,390,353) 
     (536,492) 
     (2,834,307)

    Other income (expense): 

    Interest income 
     3,420  
     3,826  
     7,718  
     4,807 
  
    Interest expense 
     (3,858) 
     (3,729) 
     (7,087) 
     (7,806)
  
    Total other income (expense) 
     (438) 
     97 
     631  
     (2,999)

    Net loss 
    $(63,596) 
    $(1,390,256) 
    $(535,861) 
    $(2,837,306)

    Weighted average common shares outstanding - basic and diluted 
     11,939,169  
     6,602,421  
     11,764,086  
     6,548,817 
  
    Net loss per common share - basic and diluted 
    $(0.01) 
    $(0.21) 
    $(0.05) 
    $(0.43)

See
accompanying notes to condensed unaudited financial statements.

F-2

SYRA
HEALTH CORP.

STATEMENTS
OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Deficit  
    (Deficit) 

    Class A  
    Convertible Class B  
    Additional